Evidence map›Paper›PMID 38698863›Full record

ArticleFrontiers in immunology2024

Development of a nano-emulsion based multivalent protein subunit vaccine against

Debaki R Howlader, Rahul Shubhra Mandal, Ti Lu, Suhrid Maiti, Zackary K Dietz, Sayan Das, Sean K Whittier, Aaron C Nagel, Satabdi Biswas, David J Varisco and 4 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Molecular Mechanisms Underlying the Pathogenicity ofMedicina (Kaunas, Lithuania) · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. International journal of molecular sciences · 2025
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Debaki R HowladerDepartment of Veterinary Pathobiology, Center for Veterinary Medicine, University of Missouri, Columbia, MO, United States.
Rahul Shubhra MandalPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Ti LuDepartment of Veterinary Pathobiology, Center for Veterinary Medicine, University of Missouri, Columbia, MO, United States.
Suhrid MaitiDepartment of Veterinary Pathobiology, Center for Veterinary Medicine, University of Missouri, Columbia, MO, United States.
Zackary K DietzDepartment of Veterinary Pathobiology, Center for Veterinary Medicine, University of Missouri, Columbia, MO, United States.
Sayan DasDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, United States.
Sean K WhittierDepartment of Veterinary Pathobiology, Center for Veterinary Medicine, University of Missouri, Columbia, MO, United States.
Aaron C NagelHafion, Inc., Lawrence, KS, United States.
Satabdi BiswasDepartment of Veterinary Pathobiology, Center for Veterinary Medicine, University of Missouri, Columbia, MO, United States.
David J VariscoDepartment of Microbial Pathogenesis, University of Maryland, Baltimore, MD, United States.
Francesca M GardnerDepartment of Microbial Pathogenesis, University of Maryland, Baltimore, MD, United States.
Robert K ErnstDepartment of Microbial Pathogenesis, University of Maryland, Baltimore, MD, United States.
William D PickingDepartment of Veterinary Pathobiology, Center for Veterinary Medicine, University of Missouri, Columbia, MO, United States.
Wendy L PickingDepartment of Veterinary Pathobiology, Center for Veterinary Medicine, University of Missouri, Columbia, MO, United States.

Funding

Vaccines to counter emerging antibiotic resistance (R01AI138970)R01AI138970 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI PICKING, WENDY L. · 2018 to 2022
$6.0M
A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosaR01AI169781 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI Wendy L. Picking · 2023 to 2026
$3.1M
Formulation of a prophylactic vaccine against Pseudomonas aeruginosaR43AI167091 · NIAID · HAFION, LLC · PI NAGEL, AARON C · 2022 to 2023
$600k
Development of a broadly protective subunit vaccine against Pseudomonas aeruginosaR21AI140701 · NIAID · UNIVERSITY OF KANSAS LAWRENCE · PI PICKING, WENDY L. · 2018 to 2019
$427k
A vaccine specifically targeting T3SS-negative Pseudomonas aeruginosaR21AI164616 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI PICKING, WENDY L. · 2021 to 2022
$423k
NIAID NIH HHS HHSN272201800043CNIAID NIH HHS R01 AI138970NIAID NIH HHS R01 AI169781NIAID NIH HHS R21 AI140701NIAID NIH HHS R21 AI164616NIAID NIH HHS R43 AI167091
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

EmulsionsPseudomonas aeruginosaPseudomonas InfectionsPseudomonas VaccinesVaccines, SubunitAnimalsAntibodies, BacterialBacterial ProteinsDisease Models, AnimalFemaleHumansMiceVaccine DevelopmentAntibodies, BacterialBacterial ProteinsEmulsionsPseudomonas VaccinesVaccines, SubunitIL-17AL-PaFnano-emulsionnanoparticle vaccinepseudomonasRNA seqT3SS vaccine

Identifiers

PMID38698863
PMCPMC11063228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.